A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintatolimod in Severe Cases of Chronic Fatigue Syndrome

Abstract

BackgroundChronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a severely debilitating disease of unknown pathogenesis consisting of a variety of symptoms including severe fatigue. The objective of the study was to examine the efficacy and safety of a TLR-3 agonist, rintatolimod (Poly I: C12U), in patients with debilitating CFS/ME.Methods and FindingsA Phase III prospective, double-blind, randomized, placebo-controlled trial comparing twice weekly IV rintatolimod versus placebo was conducted in 234 subjects with long-standing, debilitating CFS/ME at 12 sites. The primary endpoint was the intra-patient change from baseline at Week 40 in exercise tolerance (ET). Secondary endpoints included concomitant drug usage, the Karnofsky Performance Score (KPS), Activities of Daily Living (ADL), and Vitality Score (SF 36). Subjects receiving rintatolimod for 40 weeks improved intra-patient placebo-adjusted ET 21.3% (p = 0.047) from baseline in an intention-to-treat analysis. Correction for subjects with reduced dosing compliance increased placebo-adjusted ET improvement to 28% (p = 0.022). The improvement observed represents approximately twice the minimum considered medically significant by regulatory agencies. The rintatolimod cohort vs. placebo also reduced dependence on drugs commonly used by patients in an attempt to alleviate the symptoms of CFS/ME (p = 0.048). Placebo subjects crossed-over to receive rintatolimod demonstrated an intra-patient improvement in ET performance at 24 weeks of 39% (p = 0.04). Rintatolimod at 400 mg twice weekly was generally well-tolerated.Conclusions/SignificanceRintatolimod produced objective improvement in ET and a reduction in CFS/ME related concomitant medication usage as well as other secondary outcomes.Trial RegistrationClinicalTrials.gov NCT00215800

Translating nucleic acid-sensing pathways into therapies

“…Another variant, poly(I:C 12 U) (rintatolimod) has been developed for its favourable toxicity profile, which is probably due to an inability to activate MDA5. It is being clinically evaluated for the treatment of chronic fatigue syndrome 43 .…”

Inactivated vaccine with adjuvants consisting of pattern recognition receptor agonists confers protection against avian influenza viruses in chickens

“…Some agonists of the TLRs or NLRs are used as vaccine adjuvants. The poly I:C (TLR3 agonists) (Strayer et al, 2012), flagellin (TLR5 agonists)(Liu et al, 2011b), imidazoquinolines (TLR7 and TLR8 agonists) (Raman et al, 2012), CpG (TLR9 agonists) (Gupta and Cooper, 2008) are tested as vaccine adjuvants in human. The adjuvant AS04 containing ingredients derived from TLR4 agonists is licensed for use in human vaccines (Rappuoli et al, 2011).…”

Chronic Fatigue Syndrome: Where is The Reality?

“…12 The investigational immuno-modulatory doublestranded RNA drug rintatolimod (Ampligen®; Hemispherx Biopharma, Inc.) produced objective improvement in exercise tolerance and other endpoints in a phase 3 prospective, double-blind, randomized, placebo-controlled trial of 234 subjects with longstanding, debilitating ME/CFS. 13 There are several pro-inflammatory cytokines identified that are significantly elevated in samples from 200 ME/CFS patients compared with 400 ageand gender-matched controls, and that correlate with illness severity. It's an indicator that what you are seeing is real.…”